Immunai, an AI biotech company that maps the human immune system, said Thursday it expanded its collaboration with AstraZeneca in a deal that could bring Immunai up to $37.5 million in 2026 and 2027.
The agreement extends and broadens the companies’ multiyear collaboration in oncology clinical development through 2027.
Under the expanded agreement, AstraZeneca will continue to use Immunai’s AMICA-OS AI operating system, which combines a large clinical immunology database at single-cell resolution with advanced AI models of the immune system. The platform is designed to produce insights for oncology drug development, including biomarker discovery, patient stratification, mechanism-of-action analysis and dose optimization.
The expansion follows earlier collaborations between the companies, including a 2024 agreement to apply Immunai’s platform across AstraZeneca oncology clinical programs and a 2025 agreement to expand the work into inflammatory bowel disease.
“Across AstraZeneca, we are continuously investing in frontier AI models and solutions to inform clinical development decisions and derive novel mechanistically informed biomarkers,” said Jorge Reis-Filho, chief of AI for science innovation at AstraZeneca. “The expansion of this ongoing collaboration is a reflection of our conviction in the transformative potential of AI to improve patient outcomes.”
Immunai CEO Noam Solomon said AstraZeneca’s decision to deepen the collaboration showed confidence in the platform.
“We are focused on generating insights that are mechanistically grounded and clinically relevant, and collaborations like this one are how we get there,” Solomon said.
Immunai uses single-cell genomics and machine learning to decode the human immune system and support the development of new therapeutics. Its AMICA-OS platform integrates large-scale immune data with AI models to generate mechanistic and clinically relevant insights.
The company, headquartered in New York City, has a team of more than 170 experts and works with major pharmaceutical companies and academic institutions. Immunai has raised nearly $270 million to date.